Communiqués Cingulate Inc.

Actions

CING

US17248W3034

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 16:34:30 05/10/2026			Varia. 5j.	Varia. 1 janv.
4,645 ^USD	-2,42%		-0,93%	+10,02%

13/08	Cingulate Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
11/08	Cingulate publie des données évaluées par des pairs démontrant le profil pharmacocinétique différencié du CTx-1301	CI

Communiqués

17/09	Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma	AQ
13/08	Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness	AQ
11/08	Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile	AQ
30/07	Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology	AQ
02/07	Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®	AQ
16/06	Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301	AQ
04/06	Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26	NE
02/06	Cingulate Receives Complete Response Letter from FDA for CTx-1301	AQ
14/05	Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301	AQ
06/04	Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25	NE
18/03	Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights	AQ
17/02	Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules	AQ
18/11	Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25	NE
13/11	Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update	AQ
10/11	Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301	AQ
28/10/25	Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control	AQ
23/10/25	Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting	AQ
14/10/25	FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date	AQ
17/09/25	Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment	AQ
21/08/25	Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 2Q25	NE
19/08/25	Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights	AQ
15/08/25	Cingulate Provides Management Team Update	AQ
06/08/25	Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301	AQ
29/07/25	Cingulate Receives $4.3M Waiver from FDA Ahead of Imminent Filing for Marketing Approval of Lead ADHD Asset CTx-1301	AQ
09/07/25	Cingulate Appoints Nilay Patel as Chief Legal Officer to Support Growth ahead of New Drug Application	AQ